Back to search results

Continuation Study for Adagrasib in Solid Tumors

This study is for cancer patients with solid tumors (like lung or colorectal cancer) who have already been taking adagrasib (MRTX849, BMS-986503) in a previous clinical trial. It allows you to continue receiving adagrasib, either alone or with other cancer medicines like pembrolizumab, cetuximab, pemetrexed, or docetaxel. The main goal is to see how safe these treatments are over a longer period, by tracking any side effects (adverse events) that happen. You can join if your doctor believes you are still benefiting from the treatment. The study plans to include about 170 participants, but its current recruitment status is unclear.

Study design
This is an open-label, continuation study, meaning both you and your doctors will know which treatment you are receiving. It is designed to enroll about 170 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
You will be followed for side effects for up to 90 days after your last dose of treatment or when you leave the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07415031

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Recruiting
PHASE2Ages 18+InterventionalTreatment
Mirati Therapeutics Inc.
~170 participants
Updated 2026-08-18 on ClinicalTrials.gov
What's tested:AdagrasibPembrolizumabCetuximabPemetrexedDocetaxelIrinotecan

At a glance

Recruiting sites
10 of 100 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants With Adverse Events (AEs)
Measured over Up to 90 days from last dose or study discontinuation
+3 more outcomes measured

Conditions

Solid Tumors

Explore related trials

Colorectal CarcinomaLung Non-Small Cell CarcinomaSolid Neoplasm

Where it's being run

100 sites across 65 states
Italy9
Spain7
France5
Texas3
Netherlands3
South Korea3
California2
Massachusetts2

Study leadership

  • Bristol-Myers Squibb · STUDY_DIRECTOR · Bristol-Myers Squibb

Who to contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
[email protected]
855-907-3286
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participant is eligible to receive continued study treatment as per the parent study, and/or investigator assessed clinical benefit.
Individuals with assigned female sex at birth (AFSB) must have documented proof that they are not of childbearing potential. IOCBP participants who are sexually active must agree to follow the instructions for method(s) of contraception and included in the ICF.

Exclusion

Participant is not eligible for study treatment per the parent study eligibility criteria.
Participants who have completed treatment with the study drugs, progressed on prior study treatment, or discontinued study treatment due to toxicity in the parent study are not eligible to receive study drug in this study.
Participants not receiving clinical benefit from parent study drug as assessed by the investigator.

What this trial measures

  • Number of Participants With Adverse Events (AEs)Up to 90 days from last dose or study discontinuation
  • Number of Participants With AEs Leading to Treatment DiscontinuationUp to 90 days from last dose or study discontinuation
  • Number of Participants With Serious Adverse Events (SAEs)Up to 90 days from last dose or study discontinuation
  • Number of Participants With AEs Leading to DeathUp to 90 days from last dose or study discontinuation